ARS | Publication request: Generation and evaluation of a LaSota strain-based recombinant Newcastle disease virus (NDV) expressing the glycoprotein (G) of avian metapneumovirus subgroup C (aMPV-C) as a bivalent vaccine

Submitted to: Meeting Abstract
Publication Type: Abstract Only
Publication Acceptance Date: February 1, 2011
Publication Date: N/A

Technical Abstract: To develop a bivalent vaccine, a recombinant Newcastle disease virus was generated by using the NDV LaSota strain with insertion of the G gene of aMPV-C. The biological assessments of the recombinant virus, rLS/aMPV-CG, by conducting the mean death time, intracerebral pathogenicity index, and growth dynamics assays showed that rLS/aMPV-CG was slightly attenuated compared to the wild-type LoSota strain. The expression of aMPV-C G protein in rLS/aMPV-CG-infected Vero cells was detected by immunofluorescence assay. Vaccination of turkeys with rLS/aMPV-CG provided protection against NDV and aMPV-C challenges. The results suggest that this recombinant virus is a safe and potential bivalent vaccine candidate.